|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
5
|
|
gptkbp:bfsParent
|
gptkb:fulvestrant
|
|
gptkbp:activities
|
CD K4/6 inhibitor
|
|
gptkbp:appointed_by
|
oral tablet
|
|
gptkbp:approves
|
gptkb:2017
gptkb:FDA
|
|
gptkbp:can_be_used_with
|
gptkb:letrozole
gptkb:anastrozole
|
|
gptkbp:class
|
antineoplastic agent
hormonal agent
|
|
gptkbp:clinical_trial
|
Phase III
first-line therapy
second-line therapy
MONALEESA-1
MONALEESA-2
MONALEESA-3
MONALEESA-7
|
|
gptkbp:contraindication
|
severe hepatic impairment
|
|
gptkbp:developed_by
|
gptkb:Novartis
|
|
gptkbp:dosage_form
|
gptkb:tablet
|
|
gptkbp:formulation
|
film-coated tablet
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
ribociclib
|
|
gptkbp:interacts_with
|
strong CY P3 A4 inducers
strong CY P3 A4 inhibitors
|
|
gptkbp:invention
|
2027
patented
|
|
gptkbp:is_monitored_by
|
liver function tests
complete blood count
|
|
gptkbp:is_used_for
|
treatment of breast cancer
|
|
gptkbp:lifespan
|
approximately 30 hours
|
|
gptkbp:manager
|
oral
|
|
gptkbp:marketed_as
|
gptkb:Kisqali
|
|
gptkbp:pharmacokinetics
|
metabolized by CY P3 A4
|
|
gptkbp:population
|
postmenopausal women
men with breast cancer
|
|
gptkbp:provides_information_on
|
ESMO guidelines
NCCN guidelines
|
|
gptkbp:release_region
|
gptkb:Australia
gptkb:Japan
gptkb:USA
gptkb:Native_American_tribe
EU countries
|
|
gptkbp:research_focus
|
combination therapies
resistance mechanisms
biomarkers for efficacy
|
|
gptkbp:safety_features
|
generally well tolerated
|
|
gptkbp:side_effect
|
fatigue
nausea
diarrhea
thromboembolic events
neutropenia
pulmonary toxicity
cardiac toxicity
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:targets
|
gptkb:hormone_receptor-positive_breast_cancer
|
|
gptkbp:type_of_care
|
important for efficacy
|